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Plasmacytoid dendritic cells (pDCs) have been shown to both mediate and prevent autoimmunity, and
the regulation of their immunogenic versus tolerogenic functions remains incompletely understood.
Here we demonstrate that, compared to other cells, pDCs are the major expressors of Indoleamine-2,3-
dioxygenase (IDO) in steady-state lymph nodes (LNs). IDO expression by LN pDCs was closely dependent
on MHCII-mediated, antigen-dependent, interactions with Treg. We further established that IDO pro-
duction by pDCs was necessary to confer suppressive function to Tregs. During EAE development, IDO
expression by pDCs was required for the generation of Tregs capable of dampening the priming of
encephalitogenic T cell and disease severity. Thus, we describe a novel crosstalk between pDCs and Tregs:
Tregs shape tolerogenic functions of pDCs prior to inﬂammation, such that pDCs in turn, promote Treg
suppressive functions during autoimmunity.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Plasmacytoid dendritic cells (pDCs) are important sensors of
non-self-nucleic acids derived from bacteria or viruses and are
crucial mediators of innate anti-microbial responses through the
production of inﬂammatory cytokines and type-I IFNs [1,2]. In
addition, pDCs have been implicated in the development of severalal dendritic cells; BM, bone
l thymic epithelial cells; dLN,
une encephalomyelitis; IDO,
endrocyte glycoprotein; MS,
.
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Ltd. This is an open access article uautoimmune diseases, including lupus, psoriasis, multiple sclerosis
(MS) and type-1 diabetes [3e7]. Following abnormal release of self-
DNA during inﬂammatory processes, pDCs are activated through
TLR signalling and subsequently produce type-I IFN [8]. Impor-
tantly, a few years ago, the notion emerged that pDCs act not only as
innate sensors but can also function as bona ﬁde antigen (Ag) pre-
senting cells (APCs) and directly impact T cell responses [9]. It was
shown that pDCs capture and process Ags [10], and load antigenic
peptides onto MHC class I (MHCI) [11] and MHC class II (MHCII)
molecules [12e14]. Themodulation of Ag-presenting pDC functions
led to important consequences on T cell immunity, the outcome
being highly dependent on the cytokine microenvironment [15].
Many studies, including those investigating oral tolerance and
allograft models, suggest that steady-state Ag-presenting pDCs
exclusively promote T cell tolerance [16e18]. Although the nature
of the factors controlling distinct pDC functions remains to be
established, once activated, pDCs exhibit both immunogenic and
tolerogenic functions. For example, using mice exhibiting a speciﬁc
loss of MHCII expression by pDCs, we showed that CpG-B activatednder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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property that can be exploited for anti-tumor vaccines [19]. Pro-
pathogenic Ag-presenting pDCs were similarly described in a
mouse model of atherosclerosis in which pDCs induced pathogenic
Th1 cells [20]. In addition, BST-2 mediated speciﬁc Ag delivery to
CpG-activated pDCs led to cytotoxic T lymphocyte (CTL) and Th1
cell differentiation and triggered protective immunity against viral
infection and tumor growth [21]. In contrast, in the context of EAE,
Ag targeting to pDCs via Siglec-H promoted CD4þ T cell anergy and
inhibited CNS inﬂammation [22]. We previously demonstrated that
in EAE, pDCs present myelin Ags on MHCII molecules to induce the
expansion of suppressive Tregs, a phenomenon correlated with
disease amelioration [23].
Indoleamine 2,3-dioxygenase (IDO) is an immunomodulatory
enzyme involved in the initial and the rate-limiting step of tryp-
tophan catabolism. Upon inﬂammation, IDO production has been
shown to compromise T cell proliferation, promote T cell anergy
and Tregs [24e26]. Depending on the experimental context, IDO
can be induced either by IFN-g, IFN-a/b, or TGF-b. CTLA-4 binding
to cell-surface expressed costimulatory molecules promotes IDO
production by pDCs through IFN-g or IFN-a/b signalling [27e30].
Furthermore CD200-Ig binding to his cognate receptor induces IDO
in an IFN-a/b dependent signalling pathway [31]. Both IFN-g and
IFN-a/b pathways result in IDOþ immunosuppressive effects which
are closely dependent on the catalytic activity of the enzyme.
CTLA-4-binding also promote IDO in tumor contexts, but the
enzyme has reveal activity in only a minor DC subpopulation
expressing the marker CD19, but none of the pDC classical markers
[32,33]. IDO enzymatic functions in tumor dLN-sorted pDCs have
been correlated to in vitro Treg differentiation and suppressive
functions [24,34]. More recently, Pallotta and colleagues described
that IDOþ pDCs induced long-lived Tregs by using a TGF-b-
dependent pathway distinct from the catalytic activity of the
enzyme. In mouse a model of skin delayed-type hypersensitivity,
they shown that whereas IFN-g-dependent IDO enzymatic activity
in pDCs leads to T cell anergy, TGF-b induced IDO phosphorylation
results in increased Treg frequencies [35].
It is so far unknown whether IDO expression in naïve pDCs pre-
exists, and how it would be regulated in steady-state LNs. In
contrast, recent work has implicated IDO expression in pDC
immunoregulatory functions, including Treg induction, in inﬂamed
LNs. Furthermore, IDO production by tumor-associated pDCs has
been correlated to in vitro Treg-mediated suppression. However,
the nature of the cells expressing IDO, as well as the impact on Treg
functions in chronic inﬂammatory diseases, such as autoimmune
disorders, remain undetermined.
Here we show that in steady-state lymph nodes (LNs), IDO is
highly expressed by pDCs compared to other LN resident cells. We
further established that IDO expression is positively regulated in
steady-state pDCs following MHCII-mediated interactions with
Tregs. During autoimmune disorders, such as EAE, IDO expression
by MHCII competent pDCs is mandatory to confer suppressive
functions to pDC-induced Tregs. IDO-competent Ag-presenting
pDCs promote Tregs that inhibit autoimmune effector T cell re-
sponses in LNs, resulting in reduced disease severity. Therefore, we
have identiﬁed a bidirectional interaction between pDCs and Tregs
that favours self-tolerance.
2. Materials and methods
2.1. Mice
All mice had a pure C57BL/6 background and were bred and
maintained under SPF conditions at Geneva medical school animal
facility and under EOPS conditions at Charles River, France or at theNational Institutes of Health, Bethesda, US. DEREG [36], Ubiquitin-
eGFP [37], pIII þ IV/ [38], IDO/ [39], BDCA2-DTR [40], MARILYN
Rag2/, OTII Rag2/ [41], AND Rag2/ [42], SMARTA Rag1/
[43], Rag2/, Scurfy [44], CD45.1 (Charles River, France), and 2D2
[45] mice have been previously described. WT C57BL/6 mice were
purchased from Harlan laboratories (France) or Taconic (US). All
procedures were approved by and performed in accordance with
the guidelines of the animal research committee of Geneva or of the
NIH.
2.2. Generation of BM chimeric mice
BM chimeric mice were generated as described [19]. Brieﬂy, BM
cells were recovered from tibia and femurs of donor mice. 5 to
7  106 cells were injected intravenously into sub-lethally irradi-
ated recipient mice (two consecutive doses of 450 cGy). Reconsti-
tutionwas assessed by analysing blood cells by ﬂowcytometry after
6e8 weeks. For mixed BM chimeras, CD45.2 WT eGFP and CD45.2
pIII þ IV/ BM cells were simultaneously transferred into irradi-
ated CD45.1 WT recipient mice in a 1:1 ratio.
2.3. EAE experiments
Active EAE was induced by immunizing mice, subcutaneously in
both ﬂanks, with 100 mg of MOG35e55 peptide (MEVG-
WYRSPFSRVVHLYRNGK, Biotrend) emulsiﬁed in incomplete
Freund's adjuvant (BD Diagnosis) supplemented with 500 mg/ml
Mycobacterium tuberculosis H37Ra (BD Diagnosis). At the time of
immunization and 48 h later, mice also received 300 ng of pertussis
toxin (Sigma-Aldrich) into the tail vein. Mice were monitored daily
for disease clinical symptoms, and blindly scored as follows. 1,
ﬂaccid tail; 2, impaired righting reﬂex and hind limb weakness; 3,
complete hind limb paralysis; 4, complete hind limb paralysis with
partial fore limb paralysis; 5, moribund.
For passive EAE induction, encephalitogenic CD4þ T cells were
generated in vitro from LN and spleen cells of 2D2mice as described
[46]. 1e2  106 total cells were injected i.p. into recipient mice.
Mice received 67 ng of pertussis toxin at the day of cell injection
and 48 h later. Mice were monitored daily for disease clinical
symptoms as described above.
Adoptive transfers of Treg cells were performed as follows.
WT/ WT, pIII þ IV// WT and IDO// WT chimeric mice
were immunized or not with MOG35e55 þ CFA. CD4þ CD25hi T cells
were harvested from total skin LNs (naïve) or dLNs (day 10 after
EAE immunization) and 1e5  105 CD4þ CD25hi T cells were
injected intravenously into tail vein of recipient mice. EAE was
induced by active immunization the day after Treg transfer. In some
experiments, CD45.1 mice were used as recipients, and Treg
migration was assessed in dLNs at day 3 and in dLNs and SC at day
15 after EAE immunization.
Adoptive transfers of pDCs were performed as follows.
1.2e1.5  106 BM derived pDCs loaded with 10 mg/mL of MOG35e55
were injected intravenously into tail vein of recipient mice, and EAE
was induced by active immunization the day after.
In some experiments, EAE mice were treated i.p. at indicated
time points with DT (100 ng/mouse for BDCA2-DTR and 1 mg/
mouse for DEREG).
2.4. Ex vivo cell isolation
Treg cells were isolated from total skin LNs of naïvemice or from
dLNs of EAE mice (day 10 after immunization). LNs were scratched
and LN cells were subjected to CD4þ Tcell enrichment using CD4þ T
cell isolation kit (Miltenyi biotec). CD4þ CD25hi Treg cells were next
sorted using a MoFlowAstrios (Beckman Coulter).
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were recovered from LN after digestion with an enzymatic mix
containing collagenase D (1 mg/mL) and DNAse I (10 mg/mL)
(Roche) in HBSS. B cells were isolated using anti-CD19 beads
(Miltenyi Biotech), macrophages, cDCs and pDCs were then puri-
ﬁed, after CD3þ cells depletion (Miltenyi Biotech), by ﬂow cytom-
etry as CD11cCD11bþLy6Cþ for macrophages, CD11cþPDCA1- for
cDCs and CD11cintPDCA1þSiglecHþ for pDCs, using a MoFlowAs-
trios (Beckman Coulter) or BD FACSAria (BD Biosciences).2.5. In vitro BM derived DC generation
pDCs were generated from BM of WT, pIII þ IV/ and IDO/
mice as previously described [23]. Brieﬂy, BM cells were recovered
from tibia and femurs of mice and cultured, after red cell lysis, for 7
days in complete RPMI medium (10% heat-inactivated fetal bovine
serum, 50 mM 2-bMercaptoethanol, 100 mM sodium Pyruvate and
100 mM of Penicillin/Streptomycin) supplemented with 100 ng/mL
of murine Flt3L (PeproTech).
cDCs were generated as pDCs from BM of WT mice, by supple-
menting complete RPMI medium with 20 ng/ml granulocyte-
macrophage colony-stimulating factor (PeproTech), and activated
for 24 h with 5 ng/ml LPS (Enzo Life Sciences, Inc.).2.6. Co-cultures
CD4þ Tcells were recovered from scratched total skin LNs of 2D2
mice and puriﬁed with CD4þ T cell isolation kit (Miltenyi Biotec)
according tomanufacturer's instructions. Both cell types purity was
assessed by ﬂow cytometry using a Cyan™ ADP (Beckman Coulter)
and exceeded 90%.
WT and Rag2/ pDCs were recovered from total skin LN and
spleen after digestion with the enzymatic mix described above.
pDCs were isolated using the Plasmacytoid Dendritic Cell isolation
kit II (Miltenyi Biotec) according to manufacturer's instructions.
pDCs were loaded or not with MOG35e55 peptide (10 mg/mL). 300
000 pDCs were seeded in 48 well plates with 200 000 2D2 CD4þ T
cells. Cells were co-cultured in complete RPMImedium for 16 h and
pDCs were isolated again using the Plasmacytoid Dendritic Cell
isolation kit II (Myltenyi Biotech) according to manufacturer's
instructions.
WT BM-derived pDCs were generated in vitro for 7e8 days and
puriﬁed using the Plasmacytoid Dendritic Cell isolation kit II (Mil-
tenyi Biotec) according to manufacturer's instructions. Cell purity
was assessed by ﬂow cytometry using a Cyan™ ADP (Beckman
Coulter) and exceeded 90%. pDCs were loaded or not with
MOG35e55 peptide (10 mg/mL). 500 000 pDCs were seeded in 24
well plates with 300 000 2D2 CD4þ T cells or 300 000 pDCs were
seeded in 48 well plates with 100 000 2D2 CD4þ T cells or 100 000
2D2 CD4þ CD25 cells or 100 000 2D2 CD4þ CD25þ cells. Cells were
co-cultured in complete RPMI medium for 16 h and pDCs were
isolated again using the Plasmacytoid Dendritic Cell isolation kit II
(Miltenyi Biotec) according to manufacturer's instructions.
In vitro Treg suppressive assays were performed as follows.
WT/ WT and IDO// WT chimeric mice were immunized or
not withMOG35e55þ CFA. CD4þ CD25hi T cells were harvested from
total skin LNs (naïve) or dLNs (day 10 after EAE immunization) and
17 000 cells were incubated with 50 000 proliferation dye-labeled
2D2 CD4þ T cells (Treg:2D2, ratio 1:3) and 50 000 LPS activated,
MOG35e55 loaded, BM derived cDCs for 5 days. 2D2 T cell prolifer-
ation was assessed by ﬂow cytometry. The percentage of Treg-
mediated suppression was related to 0% of proliferation (relates
to 100% of suppression) in absence of cognate MOG35e55 peptide.2.7. Flow cytometry
Monoclonal antibodies used for ﬂow cytometry were from:
Biolegend; anti-CD11c (N418), anti-Ly6C (HK1.4), anti-Vb11 (KT11),
anti-CD45.2 (104); from eBioscience: anti-CD4 (GK1.5 and RM4-5),
anti-CD69 (H1.2F3), anti-CD25 (PC61.5), anti-IL10 (JES5-16E3) anti-
TER119 (TER-119), anti-Foxp3 (FJK-16s), antieIL-17 (ebio17B7),
anti-IFN-g (XMG1.2) anti-Siglec-H (ebio440c), anti-Ki67 (SolA15),
anti-CD45.1 (A20), anti-CD11b (M1/70), anti-CD11c (N418), anti-
TCRb (H57-597), anti-ICOS (C398.4A), anti-CD103 (2E7), anti CD16/
32 (93), anti-CD5 (53e7.3); from BD: anti-CD25 (PC61), anti-CD19
(1D3), anti-CD3 (145-2C11), anti-CD4 (RM54-5), anti-Ki67 (B56)
and antieIFN-g (XMG1.2). Cell proliferation was assessed using
CellTrace™ Violet Cell Proliferation Kit (ThermoFisher Scientiﬁc).
Gating on viable cells was performed using the Fixable Viability Dye
eFluor® 780 (eBioscience).
For ﬂow cytometry analysis, single cell suspensions were incu-
bated with FcBlock (anti-CD16/32 FcgRII-RIII) for 10 min, at 4 C
and stained with antibodies. Intracellular cytokine stainings were
done using the Intracellular Fixation & Permeabilisation buffer set
(eBioscience) or with the Fix & Perm kit (BD Biosciences) for IL-10.
Cell proliferation was assessed by ﬂow cytometry using anti-
emouse Ki67 and respective isotype control (Rat IgG2a, kappa). For
IFN-g, IL-17 and IL-10 staining, cells were re-stimulated in complete
RPMI containing PMA/ionomycin, and incubated 4 h at 37 C, 5%
CO2. Golgi stop solution (BD Biosciences) was added to the last
2.5 h of culture. Data were acquired with a Cyan™ ADP or a Gallios
(Beckman Coulter) and analysed using FlowJo software (FlowJo
company). cDCs were deﬁned as CD11chiPDCA-1- and pDCs as
CD11cintPDCA-1þ or CD11cintSiglec-Hþ. B cells and macrophages
were deﬁned respectively as CD19þ and CD11bþLy6Cþ.
2.8. Quantitative RT-PCR
Total RNA was isolated and prepared with TRIzol reagent
(Invitrogen) and RT-PCR were performed as described [23]. cDNA
was synthesized with random hexamers and M-MLV Reverse
Transcriptase (Promega). PCR were performed with CFX Connect
Real-time System (Bio rad) and iQ SYBR green Super-mix (Bio-Rad
Labolatories). GAPDH mRNA was used for normalization. Primer
sequences were as follows: IDO, forward, 50-GGG ATG ACG ATG TTC
GAA AG-30 and reverse 50-CAG GAC ACA GTC TGC ATA AG-30;
GAPDH, forward, 50- CCC GTA GAC AAA ATG GTG AAG -30 and
reverse 50- AGG TCA ATG AAG GGG TCG TTG -30.
2.9. Statistics
Signiﬁcance was assessed by two-tailed Mann-Whitney test or
by one-way ANOVA with Bonferroni post Hoc test. EAE incidence
was analysed using two-way ANOVAwith Bonferroni post Hoc test.
All statistical analyses were done using Prism 5.0 software
(GraphPad Software). *P < 0.05, **P < 0.01, ***P < 0.001,
****P < 0.0001, NS ¼ Non signiﬁcant.
3. Results
3.1. IDO expression by pDCs in steady-state LN is dependent on
MHCII restricted Ag-speciﬁc interactions with Treg
We analysed IDO mRNA expression in different cell subtypes
sorted from steady-state LNs. IDO mRNA was expressed to far
greater levels (>5 fold) by pDCs (CD11cintPDCA-1þ), than by cDCs
(CD11chiPDCA-1), B cells (CD11cCD19þ), and macrophages
(CD11cCD11bþLyC6int/þ) (Fig. 1A). Consistently, IDO preferential
expression by steady-state LN pDCs compared to cDCs was also
Fig. 1. IDO expression by pDCs is induced after Ag-speciﬁc interactions with Tregs. (A) IDO mRNA expression in B cells, cDCs, pDCs and macrophages (MØ) sorted from total skin
LNs of naïve WT. (B) IDO mRNA in pDCs isolated from total skin LNs of naive WT, Rag2/, OTII Rag2/ and IDO/mice. (C) CD5 expression levels by AND Rag2/, Smarta Rag1/
(SMA) and Marilyn Rag2/ (MAR) CD4þ TCR tg T cells (left), and IDO mRNA levels in pDCs isolated from skin LN of AND, SMA, MAR and WT mice (right). (C) Foxp3þCD4þ Treg
frequencies in LNs of OTII Rag2/ and female Marilyn Rag2/ mice. (E) Foxp3þCD4þ Treg frequencies in LN cells of 2D2 TCR tg mice (left), and IDO mRNA levels in pDCs isolated
from skin LN of Rag2/mice and co-cultured in vitrowith 2D2 TCR tg CD4þ T cells and MOG35e55 peptide for 16 h (right). (F) IDO mRNA levels in ex-vivo pDCs sorted from skin LN of
3wk-old WT, pIII þ IV/ and Scurfy mice. (G) IDO mRNA levels of ex vivoWT pDCs and WT BM derived pDCs loaded or not with MOG35e55 and co-cultured in vitrowith 2D2 CD4þ T
cells for 16 h. (H) IDO mRNA levels of ex vivo WT pDCs and WT BM derived pDCs loaded with MOG35e55 and co-cultured in vitro for 16 h with 2D2 CD4þ CD25 cells, 2D2 CD4þ T
cells or 2D2 CD4þ CD25þ Treg cells. (AeH) Results are representative of at least 2 independent experiments. Error bars depict mean ± SEM. (A, B, C, G, and H) One-way ANOVAwith
Bonferroni post Hoc test or (E and F) two-tailed Mann-Whitney test was used. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, NS ¼ Non signiﬁcant.
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restricted effect (Supplementary Fig. 1A). IDO expression by pDCs
was shown to be induced by T-cell produced cytokines, such as IFN-
g and TGF-b [35,47]. To determine whether, in steady state, T cells
are involved in the regulation of IDO expression by pDCs, we
measured IDO mRNA in Rag2/ mice, which are devoid of T cells.
Compared to WT mice, pDCs from steady-state LNs of Rag2/
exhibited a signiﬁcant reduction of IDO mRNA, which was in ﬁne
comparable to levels obtained in IDO/ pDCs (Fig. 1B). We next
tested whether interactions with T cell were required for IDO in-
duction in pDCs of naïve mice. We examined IDO expression in
pDCs from LNs of mice expressing a monoclonal population of
CD4þ T cells speciﬁc to OVA peptide, OT-II Rag2/ mice. IDO
expression was signiﬁcantly reduced and was comparable to whatwas seen in Rag2/ mice (Fig. 1B). Thus, OT-II transgenic CD4þ T
cells were insufﬁcient at inducing IDO in pDCs.
This result might be explained by a low TCR self-reactivity for
MHCII molecules of the OTII transgenic CD4þ Tcells [48]. To test the
possibility that distinct TCR self-reactivity would exhibit differen-
tial ability to induce IDO expression in pDCs, we isolated pDCs from
different CD4þ TCR transgenic Rag1/ mice that express distinct
levels of CD5, which reﬂects clone-speciﬁc strength self-reactivity
[48]. Each TCR transgenic T cell population display a speciﬁc sur-
face amount of CD5 that covered a range from low (Marilyn, TCR
speciﬁc for HY), medium (Smarta, TCR speciﬁc for LCMV), to high
(AND, TCR speciﬁc for Pigeon Cytochrome c) (Fig. 1C). IDO mRNA
expressionwas reduced in LN pDCs isolated from all TCR transgenic
Rag/ mice compared to WT mice (Fig. 1C), showing that IDO
Fig. 2. IDO expression by pDCs is dependent of MHCII-TCR interactions. (A-C) Mixed
BM chimeric mice were generated by co-transferring (1:1) CD45.2 GFPþ WT and
CD45.2 pIII þ IV/ BM cells in lethally irradiated CD45.1 WT mice. (A) Experimental
design. (B) WT GFPþ cDCs and pDCs, and pIII þ IV/ cDCs and pDCs were sorted from
total skin LN of naïve mice based on CD45.2, CD11c, PDCA-1 and GFP markers. (C) IDO
mRNA expression level in indicated cells is represented. Results are representative of at
least 3 independent experiments. Error bars depict mean ± SEM. One-way ANOVA
with Bonferroni post Hoc test was used. **P < 0.01, NS ¼ Non signiﬁcant.
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native hypothesis which might explain why IDO expression in
negligible is a potential speciﬁc requirement of Tregs in regulating
IDO expression in pDCs, this population being almost absent in LNs
of the TCR transgenic T cell mice tested (Fig. 1D). Consistently,
MOG35e55-loaded Rag2/ pDCs, exhibit a signiﬁcant restoration of
IDO expression when co-cultured with 2D2 TCR tg CD4þ T cells,
which contain a low but signiﬁcant frequency of Foxp3þ cells
(Fig. 1E). Moreover, pDCs isolated from LNs of Scurfy mice, which
are devoid of Foxp3þ Tregs [44], presented a signiﬁcant reduction
of IDO mRNA expression compared to WT pDCs (Fig. 1F). Thus, our
data suggest that Tregs signiﬁcantly contribute to induce IDO
expression by pDCs in steady-state LN. We next evaluated whether
Ag-speciﬁc pDC-T cell contacts were required to promote IDO
expression in pDCs. To do so, cultures were done using in vitro
generated BM-derived pDCs, for which IDO mRNA levels were
found to be negligible, reinforcing the idea that a crosstalk with T
cells is indeed required for pDCs to competently express IDO
(Fig. 1G). When co-cultured with 2D2 TCR tg CD4þ T cells, a modest
increase in IDO mRNA expression was observed in BM-derived
pDCs (Fig. 1G). IDO expression was further increased by 2 fold
when pDCs were previously loaded with MOG35e55 peptide,
reaching similar levels of expression as pDCs isolated fromWT LNs
(Fig. 1G), Therefore, MHCII-restricted Ag-speciﬁc interactions with
CD4þ T cells signiﬁcantly contribute to the induction of IDO
expression in pDCs. To test a role for Tregs in this process, we
repeated co-culture experiments using 2D2 TCR tg CD4þ Tcells that
were separated into in CD25hi and CD25neg populations. While 2D2
TCR tg CD4þCD25neg cells were incompetent at inducing IDO, 2D2
TCR tg CD4þCD25hi cells signiﬁcantly enhanced IDOmRNA levels in
pDCs loaded with MOG35e55 (Fig. 1H), conﬁrming that Tregs are
mandatory at promoting IDO expression in pDCs. pDCs co-cultured
with total 2D2 TCR tg CD4þ T cells exhibit a slight, but not signiﬁ-
cant increase in IDO mRNA levels compared to pDCs co-cultured
with 2D2 TCR tg CD4þCD25hi cells, suggesting that although
Tregs are required to promote IDO, non-Treg CD4þ Tcells might also
contribute to this process (Fig. 1H).
To clearly demonstrate that MHCII-restricted Ag speciﬁc in-
teractions between pDCs and T cells are necessary to induce IDO in
pDCs, we used genetically deﬁcient mice that selectively lackMHCII
expression by pDCs. Thesemice have been described before and are
deﬁcient for the promoters III and IV (pIII þ IV) of CIITA, the master
regulator for MHCII expression [38]. In mice, CIITA is under the
control of cell speciﬁc promoters, pI, pIII and pIV [49,50]
(Supplementary Fig. 2). Absence of pIV leads to MHCII abrogation
on cortical thymic epithelial cells (cTECs), resulting in the lack of
CD4þ Tcell positive selection. To restore CD4þ T cell thymic positive
selection by MHCII competent cTECs, bone marrow (BM) cell pre-
cursors from pIII þ IV/ mice need to be injected into irradiated
WT recipients (pIII þ IV/ / WT) and compared to WT/ WT
controls. pIII þ IV/ / WT mice exhibiting genetic deﬁciencies
compared to WT/ WT, it is possible that distinct immunological
environments will affect IDO expression by pDCs. Therefore, to
immerse MHCII competent and deﬁcient pDCs in an identical
milieu, we performedmixed BM chimeric mice using BM cells from
Ubi-eGFPWTand pIIIþ IV/mice (ratio 1:1) that were co-injected
into irradiated recipient mice expressing the congenic marker
CD45.1 (Fig. 2A). LN cells were sorted 2 months later as pDCs and
cDCs from donor BM cells (gated on CD45.2þ) and further separated
as WT (eGFPþ) or pIII þ IV/ (eGFP) cells (Fig. 2A and B). We
conﬁrmed that cDCs expressed little IDO mRNA (Fig. 2C). IDO
expression by MHCII deﬁcient pDCs was impaired compared to
MHCII competent pDCs in mixed BM chimeric mice (Fig. 2C). Since
cells were isolated from the same LNs, decreased IDO expression in
absence of MHCII expression by pDCs was not related to differentcytokine expression proﬁles, but linked to a defective MHCII
expression by pDCs. An alternative explanation is that CIITA directly
acts as a transcription factor regulating IDO gene expression.
However, we observed a similar reduction of IDO mRNA in pDCs
isolated from H2-Db/ mice (not shown), ruling out this hypoth-
esis. Altogether, our data demonstrated that MHCII-restricted Ag
speciﬁc interactions with Tregs are required for the induction of
IDO expression by pDCs in steady-state LNs.3.2. IDO expression in LNs is restricted to pDCs during EAE, and is
impaired in MHCII/ pDCs
We next evaluated whether, as in steady-state LNs, pDCs re-
mains the major expressors of IDO in LNs in a model of chronic
inﬂammation. IDO has been shown to exert a protective role in EAE
using either IDO/ mice or IDO blocking antibodies [51,52].
Therefore, we have quantiﬁed IDO mRNA expression in different
cell types sorted from LNs draining the site of EAE immunization
(day 10) in wild type (WT) mice. IDO was predominantly (>5 fold)
expressed by pDCs compared to other LN cells (Fig. 3A). Levels of
expression were comparable to steady-state LN pDCs
(Supplementary Fig. 3A). Next, we analysed IDO expression by
MHCII deﬁcient pDCs during EAE. pDCs and cDCs were sorted from
draining LNs of WT/ WT and pIII þ IV// WT mice 10 days
after EAE induction. Again, cDCs expressed little IDO mRNA
Fig. 3. MHC-II sufﬁcient pDC express IDO during EAE. (A) IDO mRNA expression in B cells, cDCs, pDCs and macrophages (MØ) sorted from dLNs of WT EAE mice 10 days after
immunization. (B) EAE was induced in WT / WT and pIII þ IV/ / WT chimeric mice, and IDO mRNA was measured in cDCs and pDCs sorted from dLN 10 days after im-
munization. (C) Mixed BM chimeric mice were generated by co-transferring (1:1) CD45.2 GFPþWTand CD45.2 pIII þ IV/ BM cells in lethally irradiated CD45.1 WT mice. WT GFPþ
cDCs and pDCs, and pIII þ IV/ cDCs and pDCs were sorted from dLNs 10 days after EAE induction based on CD45.2, CD11c, PDCA1 and GFP markers. IDO mRNA expression level in
indicated cells (AeC) Results are representative of at least 3 independent experiments. Error bars depict mean ± SEM. One-way ANOVA with Bonferroni post Hoc test was used.
*P < 0.05, ****P < 0.0001, NS ¼ Non signiﬁcant.
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pDCs sorted from pIII þ IV/ / WT compared to WT / WT
chimeras (Fig. 3B). Differential IDO expression byMHCII competent
and MHCII deﬁcient pDCs might be explained by distinct inﬂam-
matory cytokinic environments in WT / WT and pIII þ IV/
 / WT mice, as the latter developed more severe EAE [23].
Therefore, we performed mixed BM chimeric mice using as before
BM cells from Ubi-eGFP WT and pIII þ IV/ mice (ratio 1:1) that
were injected into irradiated CD45.1 recipient mice. EAE was
induced in mixed BM chimeric mice, and LN cells were sorted 10
days after immunization as pDCs and cDCs from donor BM cells
(gated on CD45.2þ) and further separated as WT (eGFPþ) or
pIIIþ IV/ (eGFP) cells. IDO expressionwas signiﬁcantly impaired
in MHCII deﬁcient compared to MHCII competent pDCs isolated
from LN of EAE mice (Fig. 3C). Therefore, decreased IDO expression
in absence of MHCII expression by pDCs was not related to different
cytokine expression proﬁles between WT / WT and pIII þ IV/
 / WT chimeras during EAE, but rather linked to a defective
MHCII expression by pDCs. Altogether, our data suggest that IDO
expression by LN pDCs is dependent on their expression of MHCII
molecules, independent on the inﬂammatory status of the mice,
and reﬂects a more general regulation of IDO protein expression at
the mRNA level.3.3. IDO deﬁciency leads to exacerbated encephalitogenic T cell
priming
To investigate the role of pDC-induced Treg in EAE pathogenesis,
we have induced EAE in mice lacking Treg and MHCII expression by
pDCs. We backcrossed DEREG mice, in which Foxp3þ Tregs can be
selectively depleted using diphtheria toxin (DT) injection [36], with
pIII þ IV/ mice and generated DEREGxpIII þ IV/ / WT chi-
meras (Supplementary Fig. 4 AeC). In untreated mice, as previously
described [23], EAEwas exacerbated (Supplementary Fig. 4D) when
pDCs did not express MHCII. Moreover, EAE clinical course was
similarly aggravated in DEREG / WT treated with DT and
DEREGxpIII þ IV/ / WT chimeras injected or not with DT
(Supplementary Fig. 4D). Encephalitogenic Th1 and Th17 CD4þ T
cell frequencies were increased in DT-injected DEREG/WT and
DEREGxpIII þ IV/ / WT mice compared to un-injected
DEREG / WT mice (Supplementary Fig. 4E). This demonstrates
that the depletion of Tregs and the absence of MHCII expression by
pDCs similarly enhance pathogenic T cell priming and disease
severity. Altogether, our data show that pDC-instructed Tregsinhibit the priming of encephalitogenic T cells in LNs during EAE.
We next evaluated whether IDO was implicated in the regula-
tion of encephalitogenic T cell priming during EAE. Knowing that
MHCII deﬁcient pDCs exhibit impaired IDO expression both in
steady-state and during EAE (Figs. 2C and 3C), we analysed EAE
development in WT/ WT, pIII þ IV//WT and IDO//WT
chimeric mice. As before, disease was exacerbated in mice lacking
MHCII on pDCs (pIII þ IV/ / WT) compared to control
WT/WT animals (Fig. 4A). This could be consequent to either an
absence of Ag-presentation by pDCs and/or a resulting defect in IDO
expression by pDCs from pIII þ IV/ / WT mice. Consistently
with previously published data [51,52], mice deﬁcient for IDO
(IDO// WT) developed aggravated EAE compared to WT con-
trols. Importantly, clinical scores of IDO//WTwere comparable
to mice lacking MHCII on pDCs (Fig. 4A). Notably, we did not notice
any signiﬁcant impact of IDO deﬁciency during EAE induced by
transferring MOG35e55-speciﬁc 2D2 CD4þ effector T cells (Fig. S5),
suggesting a critical role for IDO in the modulation of pathogenic T
cell priming in SLOs during EAE. To conﬁrm this hypothesis, we
measured effector cytokine production by T cells before clinical
symptom appearance (day 9) in IDO//WT, pIII þ IV//WT
and WT / WT chimeras. Elevated IFN-g and IL-17 producing
encephalitogenic CD4þ T cell frequencies were observed in LNs of
IDO deﬁcient mice (IDO/ / WT) and mice lacking MHCII
expression by pDCs (pIII þ IV// WT) compared to WT/ WT
controls, (Fig. 4B). Foxp3þCD25hi Treg proliferationwas impaired in
pIII þ IV/ / WT mice, whereas it was unaffected in IDO/
 / WT mice (Fig. 4C, left), showing that MHCII-mediated Ag
presentation, but not IDO expression by pDCs, promoted Foxp3þ
Treg proliferation. The proliferation of Foxp3þ Tregs exhibiting a
suppressive phenotype (CD103þICOSþ) [53] (Fig. 4C middle), as
well as the frequency of IL-10 expressing Foxp3þ Tregs (Fig. 4C
right), were signiﬁcantly decreased in LNs from both pIII þ IV/
 / WT and IDO/ / WT compared to WT / WT mice. Our
results identify a new role for IDO in impacting the ability of Tregs
to suppress encephalitogenic T cells in LNs.3.4. IDO deﬁciency in MOG35e55-presenting pDCs leads to EAE
exacerbation
We have shown that IDO mRNAwas preferentially expressed by
pDCs compared to other LN cells both in steady-state and during
EAE (Figs. 1A and 3A). However, whether restricted IDO expression
by pDCs is sufﬁcient and required to inhibit disease development
Fig. 4. IDO is required during EAE priming phase (A-C) EAE was induced in WT/WT (-), pIII þ IV//WT (B) and IDO//WT ( ) BM chimeras. (A) Clinical scores were
followed daily (two-way ANOVA with Bonferroni post Hoc test). Frequencies of (B) IFN-gþ (left) and IL-17þ (right) CD4þ T cells, (C) Ki67þ (left), Ki67þCD103þICOSþ (middle) and
IL10þ (right) among CD25hiFoxp3þCD4þTregs in dLN at d9 (one-way ANOVA with Bonferroni post Hoc test). (AeC) Results are representative of at least 3 independent experiments
with 8 mice per group. Error bars depict mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, NS ¼ Non signiﬁcant.
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in which endogenous pDCs were depleted following DT injection
[54]. It has been demonstrated that active immunization induces
DT toxicity, and may therefore confound experiments in DTR
transgenic mice for neuroinﬂammatory models, such as EAE [55].
To avoid this problem, we generated BM chimeric mice by injecting
BM cells from BDCA-2 DTR into irradiated WT recipients. In these
chimeric mice, no signs of toxicity or lethality in DT-treated mice
upon EAE inductionwere observed. Moreover, efﬁcient depletion of
endogenous pDCs in the blood and LNs of BDCA-2 DTR / WT
chimeras was achieved after DT injection (not shown). We trans-
ferred (i.v.) MOG35e55-loaded WT or IDO/ pDCs into DT-treated
BDCA-2 DTR / WT chimeras one day prior to EAE induction. In
these settings, IDO was selectively supplied - or not - by adoptively
transferred pDCs. Following EAE induction, onlyWT, but not IDO/
pDCs signiﬁcantly inhibited disease development (Fig. 5A).
Foxp3þCD25þ Treg proliferation was increased in LN upon pDC
transfer compared to control BDCA-2 DTR / WT EAE mice,
whether transferred pDCs expressed IDO or not (Fig. 5B), con-
ﬁrming that IDO expression by pDCs is not involved in MHCII-
dependent, pDC-mediated, Treg expansion. In contrast, the fre-
quencies of suppressive Tregs co-expressing CD103 and ICOS
(Fig. 5C), expressing high levels of CD25 (Fig. 5D), or upregulating
the activation marker CD69 (Fig. 5E), were signiﬁcantly reduced in
LN from BDCA-2 DTR / WT EAE mice transferred with IDO/
pDCs compared toWT pDCs. These results demonstrate that during
EAE, IDO expression by pDCs is required to elicit pDC-mediated
suppressive Tregs.3.5. IDO is required for in vivo Treg-mediated EAE suppression
We next tested the in vivo suppressive activity of Tregs primed
during EAE in pIII þ IV// WT, IDO// WT and WT/ WT
chimeric mice. Puriﬁed CD4þCD25þ cells, which are predominantly
Foxp3þ for all conditions (Fig. 6A), were transferred into WT hosts
one day prior to EAE induction (Fig. 6A and B). Tregs primed in WT
mice reduced EAE incidence, delayed disease onset, and conferred
signiﬁcant protection as we have previously reported [23]. In
contrast, Tregs primed in mice lacking MHCII expression by pDCs
did not exhibit any suppressive activity (Fig. 6B and Table 1).
Strikingly, Tregs primed in absence of IDO did not confer any delay
in disease onset, nor reduced EAE severity (Fig. 6B and Table 1).
Frequencies of donor Tregs primed in WT and IDO/ mice were
similar in dLNs (day 3) and dLNs and SC (day 15) of recipient mice.
These results suggest that the absence of EAE protection by Tregs
primed in IDO deﬁcient mice does not rely on an impaired migra-
tion of donor cells, but rather results from impaired intrinsic sup-
pressive functions (Supplementary Fig. 6A and B). Accordingly,
compared to Tregs isolated fromWT EAEmice, Tregs primed in IDO
deﬁcient EAE mice were signiﬁcantly less efﬁcient at suppressing
MOG35e55 loaded DC induced 2D2 CD4þ T cell proliferation in vitro
(Fig. 6C). Furthermore, Tregs isolated from naïve WT and IDO/
mice did not confer any suppression, further suggesting that Ag-
speciﬁc priming in IDOþ context is required for the acquisition of
Treg suppressive functions (Fig. 6C). In agreement, in vivo, only
Tregs activated following EAE immunization in WT mice efﬁciently
inhibited EAE incidence and severity (day 14), whereas neither
Tregs isolated from naïve WT, nor Tregs isolated from naïve or
immunized IDO/ mice, conferred any protection upon transfer
into EAE mice (Fig. 6D). Therefore, EAE-mediated activation is
Fig. 5. IDOþ pDCs drive suppressive Tregs during EAE. (AeE) MOG35e55 loaded BM-
derived pDCs from WT (-) and IDO/ ( ) were transferred (arrow) or not (B) into
BDCA2-DTR / WT BM chimeras and EAE was induced 1 day after. Mice received 5
consecutive DT injections every 3e4 days. (A) Clinical scores were followed daily (two-
way ANOVA with Bonferroni post Hoc test). Frequencies of (B) CD4þCD25þ Foxp3þ
Treg cells (one-way ANOVAwith Bonferroni post Hoc test), (C) CD103þICOSþ Tregs, (D)
CD25high Tregs and (E) CD69þ Tregs from dLNs are represented at d10 after EAE im-
munization (two-tailed Mann-Whitney test). (AeE) Results are representative of at
least 2 independent experiments with 6e8 mice per group. Error bars depict
mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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Altogether, our data demonstrate that IDO provided by pDCs is
critical for the acquisition of Ag-speciﬁc Treg in vivo suppressive
functions.4. Discussion
Whether pDCs exhibit tolerogenic or immunogenic APC func-
tions in different immunogical context is an important matter of
debate, and might depend on their own ability to produce in-
ﬂammatory cytokines, as suggested by previous studies [9]. pDC
tolerogenicity has been correlated to their expression of IDO in
different settings [24,31,35]. In a mouse model of skin inﬂamma-
tion, IDO was induced in pDCs either after IFN-g or TGF-b stimu-
lation, the ﬁrst pathway promoting IDO enzymatic activity-
dependent tryptophan depletion, the second one implicating IDO
phosphorylation and subsequent Treg induction [35]. Here we
show that already in steady-state, pDCs are the major expressors of
IDO in LNs. We further provide evidence that IDO expression in
naïve pDCs is regulated through Ag-speciﬁc MHCII-restricted
interactionwith Foxp3þ Tregs. First, pDCs isolated from TCR tgmice
in which CD4þ T cells all recognize a non-expressed antigenic
peptide, exhibited substantially reduced IDO expression, indepen-
dently of the self-reactivity of the TCR. Second, in absence of an
existing Treg population in those TCR tg mice, LN pDCs exhibited a
dramatic reduction in IDO expression. In addition, pDCs isolated
from LN of Treg-deﬁcient Scurfy mice expressed very little IDOmRNA.We cannot exclude that in Scurfy mice, the non-Treg CD4þ T
cell population, which is strongly biased towards a pro-
inﬂammatory autoimmune repertoire compared to WT mice,
might impact IDO expression. Nevertheless, IDO expression by
pDCs from T cell deﬁcient mice was induced after co-culture with a
CD4þ T cells only when the later contained a descent Treg popu-
lation. In addition, IDO restoration was further dependent on the
presence of the cognate antigenic peptide. The contribution of Treg
in inducing IDO in pDCs has been suggested before [56], however
without real evidence for a requirement of MHCII-restricted, Ag-
speciﬁc interactions between pDCs and Tregs. Whether a particular
Treg subpopulation would be speciﬁcally involved in this crosstalk
with pDCs to induce IDO expression, and possibly the expression of
other genes as well, remains to be determined. A role for IL-10 has
been demonstrated in IDO expression stabilization [57]. Therefore,
it is possible that IL-10 producing Tregs might be more competent
to induce IDO up-regulation in pDCs. Our results reinforce the idea
that Treg exhibit their Ag-speciﬁc immunomodulatory roles by
impacting different cellular targets, not only by inhibiting effector T
cells [58], inducing tumor-associated DC death [59] but also by
promoting pDC tolerogenic functions. Future investigations will
determine whether other pDC-speciﬁc tolerogenic features simi-
larly depend on interactions with Tregs.
IDO expression by DCs has also been correlated with high levels
of ICOS [60] and CTLA-4 expression by T cells, and might depend, or
not, on IFN-g production [28,31e33,61]. Inmixed BM chimericmice
containing both MHCII sufﬁcient and deﬁcient pDCs, IDO is selec-
tively abolished in MHCII deﬁcient pDCs, whereas the same Treg
populations expressing a certain level of ICOS, CTLA-4 or other
molecules are present. Therefore, although ICOS and CTLA-4 might
be required to promote IDO in pDCs, cells nevertheless need to
express MHCII molecules.
During EAE, mice lackingMHCII on pDCs developed exacerbated
disease, with increased IFN-g and reduced TGF-b production in LNs
compared to WTmice [23]. MHCII-deﬁcient pDCs nevertheless still
exhibit a strong impairment in IDO expression upon EAE. Therefore,
neither IFN-g, nor TGF-b, was sufﬁcient to induce IDO in absence of
MHCII expression by pDCs. In addition, we show that pDCs toler-
ogenicity in EAE context is dependent on their expression of IDO.
First, in IDO deﬁcient mice, encephalitogenic T cell frequency was
increased, and as a consequence, disease was exacerbated. Second,
adoptively transferred Tregs inhibited EAE only when isolated from
activelyMOG35e55 immunizedWT, but not IDO/mice, suggesting
that Tregs need to be primed in an IDO sufﬁcient microenviron-
ment to acquire their suppressive functions. Third, in LNs, IDO was
predominantly expressed by pDCs, in both naïve and EAE mice.
Finally, in an experimental setting in which we controlled IDO
expression exclusively in pDCs, we observed an inhibition of EAE, as
well as an increase in suppressive Tregs, only when pDCs expressed
IDO. Notably, Treg induced after Ag-speciﬁc interaction with IDOþ
pDCs are necessary to inhibit pathogenic T cells in LNs. Altogether,
our results demonstrate that IDO expression by pDCs is required for
the generation of suppressive Tregs that, upon Ag-speciﬁc activa-
tion, competently inhibit encephalitogenic T cells during EAE
priming phase. In conclusion, we showed that naïve pDCs are high
IDO expressors in the LN, a property acquired after a cross-talk with
Foxp3þ Tregs. By expressing IDO, pDCs become competent to confer
suppressive functions to Tregs in the context of EAE, where Ag-
presenting IDOþ pDCs promote suppressive Tregs that inhibit the
priming of encephalitogenic Th1 and Th17 cells and dampen CNS
autoimmunity. Future investigations will determine whether other
pDC features and functions, apart from IDO expression, are
impacted following interactions with Tregs. Together, our data have
identiﬁed a new regulatory role for Tregs in shaping Ag-presenting
pDC functions towards tolerogenicity in autoimmunity.
Fig. 6. Tregs primed by IDOþ pDCs are suppressive in vivo and control EAE development. (A, B) CD4þCD25hi cells were puriﬁed from dLNs of WT/WT, pIII þ IV//WT and
IDO// WT BM chimeras 10 days after EAE induction, and transferred (arrow) into WT recipients further immunized for EAE the day after. (A) Experimental design is repre-
sented. Foxp3 expression in sorted cells. (B) Clinical scores were followed daily in control mice (⊡) and in mice transferred with WT Treg (-), IDO/ Tregs ( ) or pIII þ IV/ Tregs
(B) (two-way ANOVA with Bonferroni post Hoc test). (A, B) Results are representative of at least 2 independent experiments. Error bars depict mean ± SEM. *P < 0.05, **P < 0.01.
See also Table 1. (C, D) CD4þCD25hi cells were puriﬁed from total skin LNs of naïve WT/ WT and IDO//WT BM chimeras or from dLNs of WT/ WT and IDO//WT BM
chimeras 10 days after EAE induction. (C) CD4þCD25hi cells were with proliferation dye-labeled 2D2 CD4þ T cells and LPS activated, MOG35e55 loaded, cDCs. 2D2 T cell proliferation
was assessed after 5 days. Flow cytometry histograms represent 2D2 T cell proliferation for indicated conditions. Histograms represent the percentages of Treg-mediated sup-
pression (two-tailed Mann-Whitney test). Results are representative of 2 independent experiments. Error bars depict mean ± SEM. **P < 0.01, NS ¼ Non signiﬁcant. (D) CD4þCD25hi
cells were transferred into WT recipients further immunized for EAE the day after. Clinical scores and incidence (d15) are depicted. Data are representative of 2 experiments. Error
bars represent mean ± SEM. One-way ANOVA with Bonferroni post Hoc test was used. *P < 0.05.
Table 1
Tregs primed by IDOþ pDCs delay and dampen clinical EAE. CD4þCD25hi cells were puriﬁed from dLNs of WT/WT (WT Tregs), pIII þ IV//WT (pIII þ IV/ Tregs) and
IDO//WT (IDO/ Tregs) BM chimeras 10 days after EAE induction, and transferred into WT recipients further immunized for EAE the day after. Mean and cumulative
clinical scores, mean day of onset and disease incidence are indicated (two-way ANOVA with Bonferroni post Hoc test). Results are representative of 2 independent exper-
iments. ***P < 0.001.
Mean clinical score Cumulative clinical score Mean day of onset Incidence
Ctrl EAE 1.32 ± 0.32 25.13 10 100%
EAE þ WT Tregs ***0.57 ± 0.17 10.80 16 80%
EAE þ IDO/ Tregs 1.70 ± 0.39 32.25 11 100%
EAE þ pIII þ IV/ Tregs 1.36 ± 0.36 25.88 12 100%
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